American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer

Ca-A Cancer Journal for Clinicians - Tập 62 Số 3 - Trang 147-172 - 2012
Debbie Saslow1, Diane Solomon2, Herschel W. Lawson3, Maureen Killackey4, Shalini Kulasingam5, Joanna M. Cain6, Francisco García7, Ann Moriarty8, Alan G. Waxman9, David C. Wilbur10, Nicolas Wentzensen11, Levi S. Downs12, Mark Spitzer13, Anna‐Barbara Moscicki14, Eduardo L. Franco15, Mark H. Stoler16, Mark Schiffman17, Philip E. Castle18,19, Evan R. Myers18,20
1Director, Breast and Gynecologic Cancer, Cancer Control Science Department, American Cancer Society, Atlanta, GA, on behalf of the Steering Committee, Data Group, and Writing Committee
2Senior Investigator, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, on behalf of the Steering Committee
3Adjunct Associate Professor, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, on behalf of the Data Group
4Deputy Physician in Chief, Medical Director, Memorial Sloan-Kettering Cancer Center Regional Network, Department of Surgery, Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, on behalf of Working Group 1
5Assistant Professor, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, on behalf of Working Group 1
6Professor and Vice Chair, Department of Obstetrics and Gynecology, University of Massachusetts School of Medicine, Worcester, MA, on behalf of Working Group 2
7Professor and Director, Center of Excellence in Women's Health, Mel and Enid Zuckerman College of Public Health, University of Arizona at Tucson, Tucson, AZ, on behalf of Working Group 6
8Director, Department of Esoteric Testing, AmeriPath Indiana, Indianapolis, IN, on behalf of Working Group 6
9Professor, Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, NM, on behalf of Working Group 3a
10Professor of Pathology, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, on behalf of Working Group 3b
11Investigator, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD
12Director, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women's Health, Masonic Cancer Center, University of Minnesota Medical School, Minneapolis, MN, on behalf of Working Group 4
13Professor of Clinical Obstetrics and Gynecology, Weill Medical College of Cornell University, New York, NY, on behalf of Working Group 4
14Professor, Department of Pediatrics, University of California at San Francisco, San Francisco, CA, on behalf of Working Group 5
15Professor, Departments of Oncology and Epidemiology, McGill University, Montreal, Quebec, Canada
16Professor of Pathology and Clinical Gynecology, Associate Director of Surgical and Cytopathology, Surgical Pathology, Department of Pathology, University of Virginia Health System, Charlottesville, VA
17Senior Investigator, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD
18Dr. Castle and Dr. Myers are co-senior authors.
19Executive Director, American Society for Clinical Pathology Institute, Washington, DC, on behalf of the Writing Committee
20Professor, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC

Tóm tắt

AbstractAn update to the American Cancer Society (ACS) guideline regarding screening for the early detection of cervical precancerous lesions and cancer is presented. The guidelines are based on a systematic evidence review, contributions from 6 working groups, and a recent symposium cosponsored by the ACS, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology, which was attended by 25 organizations. The new screening recommendations address age‐appropriate screening strategies, including the use of cytology and high‐risk human papillomavirus (HPV) testing, follow‐up (eg, the management of screen positives and screening intervals for screen negatives) of women after screening, the age at which to exit screening, future considerations regarding HPV testing alone as a primary screening approach, and screening strategies for women vaccinated against HPV16 and HPV18 infections. CA Cancer J Clin 2012. © 2012 American Cancer Society.

Từ khóa


Tài liệu tham khảo

10.3322/canjclin.52.6.342

10.1097/LGT.0b013e3181585870

10.1002/(SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-#

10.1023/A:1018435522475

Parkin DM, 2006, Chapter 2: The burden of HPV‐related cancers, Vaccine., 24, S3/11

10.3322/caac.20138

2012, American Cancer Society. Cancer Facts & Figures 2012

10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

10.1016/S1470-2045(10)70230-8

10.1056/NEJMoa021641

10.1056/NEJMp020178

10.1016/S0140-6736(07)61416-0

Mosher WD, 2005, Sexual behavior and selected health measures: men and women 15‐44 years of age, United States, 2002, Adv Data, 1

10.1086/516784

10.1093/jnci/djn044

10.1136/bmj.b2569

10.1093/jnci/djq356

10.1016/S1470-2045(08)70103-7

10.1097/AOG.0b013e3181e3e719

10.1016/S0002-9378(03)00418-6

10.1093/jnci/95.1.46

10.1136/bmj.a1754

10.1158/1055-9965.EPI-11-0206

Freeman H, 2005, Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities

Division of Cancer Prevention and Control National Center for Disease Prevention and Health Promotion Centers for Disease Control and Prevention. Cervical Cancer. Atlanta GA: 2011. Available at:http://www.cdc.gov/cancer/cervical/. Accessed October 21 2011.

10.1016/j.ypmed.2007.06.007

10.1002/cncr.25065

10.1309/PT3PNC1QL2F4D2VL

10.1097/AOG.0b013e31818f5008

10.1158/1078-0432.CCR-04-2599

10.1136/bmj.a1284

10.1016/j.amjmed.2004.08.021

10.1097/LGT.0b013e3181cec411

10.1097/AOG.0b013e3181c6f8a4

10.1097/01.AOG.0000296488.85807.b3

10.1001/jama.2009.1569

10.1002/ijc.21955

10.1056/NEJMoa071430

10.1056/NEJMoa073204

10.1016/S0140-6736(07)61450-0

10.1016/S1470-2045(09)70360-2

10.1136/bmj.c1804

10.1016/S1470-2045(11)70188-7

10.1177/002215540104900918

10.1309/BA43HMCAJ26VWQH3

10.1309/84E5WHJQHK83BGQD

10.1002/ijc.24010

10.1309/RNF3C01JKADQCLKP

10.1309/AJCPRI8XPQUEAA3K

10.1016/j.jcv.2004.12.011

10.1136/bmj.39493.646875.AE

10.1136/bmj.39504.506319.80

10.1136/bmj.39490.551019.BE

10.1136/bmj.39489.470347.AD

10.1136/bmj.a744

10.1136/bmj.39500.677199.AE

Kaplan JE, 2009, Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV‐infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America, MMWR Recomm Rep., 58, 1

10.1097/LGT.0b013e3181d95ad6

10.1136/bmj.b2968

10.3322/canjclin.57.1.7

Markowitz LE, 2007, Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep., 56, 1

10.1001/archinte.168.17.1881

Kulasingam S, 2011, Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force. AHRQ Pub. No. 11‐05157‐EF‐1

10.1038/bjc.1996.196

10.1038/sj.bjc.6600974

10.1001/jama.297.8.813

10.1086/320696

10.1038/sj.bjc.6602002

10.1097/01.AOG.0000120143.50098.c7

10.1093/jnci/dji162

10.1097/00006250-200301000-00010

10.1034/j.1600-0412.1998.770219.x

10.1056/NEJMoa035419

10.1016/S1470-2045(11)70145-0

2011, Australian Institute of Health and Welfare. Cervical Screening in Australia 2008‐2009. Canberra, Australian Capital Territory

10.1158/1055-9965.EPI-05-0231

10.1002/cncr.20064

10.1097/01.AOG.0000109426.82624.f8

10.1001/archinternmed.2010.134

Arbyn M, 2006, Chapter 9: Clinical applications of HPV testing: a summary of meta‐analyses, Vaccine., 24, S3/78

10.1001/jama.285.11.1500

10.1016/S1470-2045(09)70156-1

10.1016/S1470-2045(09)70246-3

10.1007/BF03404377

10.1016/j.ygyno.2006.08.053

10.1038/bjc.1995.172

10.1038/sj.bjc.6601754

10.1002/ijc.22357

10.1093/jnci/djj067

10.1016/S0002-9378(03)00413-7

10.1002/ijc.24752

10.1093/jnci/dji187

10.1309/AJCPTUS5EXAS6DKZ

10.1093/jnci/djr283

10.1093/jnci/djn510

10.1002/ijc.25396

10.1038/sj.bjc.6690523

10.1016/S0140-6736(03)14955-0

10.1309/AJCPAZV88VIFZSFD

10.1158/0008-5472.CAN-06-1057

10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z

10.1038/sj.bjc.6602049

10.1309/AJCPZ5JY6FCVNMOT

10.1097/01.AOG.0000263461.71732.40

10.1093/jnci/dji186

10.1097/AOG.0b013e3181996ffa

10.7326/0003-4819-148-7-200804010-00004

10.1016/S1470-2045(08)70208-0

Leinonen M, 2009, Age‐specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting, J Natl Cancer Inst., 101, 1612, 10.1093/jnci/djp367

10.1016/j.ejca.2011.01.008

Vesco K, 2011, Screening for Cervical Cancer: A Systematic Evidence Review for the US Preventive Services Task Force. Evidence Synthesis No. 86. AHRQ Pub. No. 11‐05156‐EF‐1

10.1371/journal.pone.0012724

10.1002/cncr.23747

Mandelblatt J, 1986, Gynecological care of elderly women. Another look at Papanicolaou smear testing, JAMA., 256, 367, 10.1001/jama.1986.03380030069030

10.1097/00006250-200008000-00012

10.1093/jnci/dji115

10.1093/jnci/djp089

10.1002/ijc.21604

10.1093/jnci/djq001

10.1002/cncr.23757

10.1056/NEJM199611213352103

10.1016/0002-9378(95)90262-7

10.3122/15572625-13-4-233

10.1016/S0002-9378(99)70601-0

10.1111/j.1471-0528.1992.tb14440.x

Centers for Disease Control and Prevention (CDC), 2011, National and state vaccination coverage among adolescents aged 13 through 17 years–United States, 2010, MMWR. Morb Mortal Wkly Rep., 60, 1117

10.1056/NEJMoa061741

10.1086/522864

10.1016/S0140-6736(07)60852-6

10.1086/597307

10.1093/jnci/djp534

10.1016/S0140-6736(09)61248-4

10.1016/S0140-6736(09)61567-1

10.1093/eurpub/ckn064

10.1016/j.vaccine.2007.04.086

10.1038/sj.bjc.6605528

10.1016/j.vaccine.2011.07.096

10.3201/eid1301.060438

10.1159/000214924

10.1080/00016340802566770

10.1093/jnci/djh104

10.1001/jama.290.6.781

10.1038/sj.bjc.6604162

10.1016/j.ejca.2010.06.016

10.1071/SH07043

10.1016/j.vaccine.2007.09.035

10.1017/S0266462309090217

10.1093/jnci/djn019

Franco EL, 2006, Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination, Vaccine., 24, S3/171

10.1016/j.arcmed.2009.06.003

10.1002/ijc.24000

New Mexico Human Papillomavirus (HPV) Pap Registry (NMHPVPR) and HOPE Clinic (House of Prevention Epidemiology). Available at:http://www.unm.edu/∼nmhpvpr/. Accessed January 15 2012.

10.1007/s10552-011-9877-6

Public Health Agency of Canada. Performance Monitoring for Cervical Cancer Screening Programs in Canada, 2009, Report From the Screening Performance Indicators Working Group, Cervical Cancer Prevention and Control Network. Ottawa, Ontario

Belinson JL, Improved sensitivity of vaginal self‐collection and high‐risk human papillomavirus testing [published online ahead of print May 31, 2011], Int J Cancer.

10.1016/j.ypmed.2011.03.018

10.1001/jama.2011.1800

10.1016/S1470-2045(11)70296-0

Thông tin
Thông tin xuất bản

Ca-A Cancer Journal for Clinicians

Tập 62 Số 3

147-172

Thông tin tác giả